Cergentis provides services and kits for complete gene sequencing based on its proprietary Targeted Locus Amplification (TLA)  Technology.


In combination with Next Generation Sequencing technologies, the TLA Technology enables the complete targeted sequencing of any genomic locus of interest. The TLA Technology is hypothesis neutral and enables the detection of all single nucleotide and structural variants.


Cergentis' TLA technology presents unique advantages in genetic research, the (deep) sequencing of candidate genes, genetic diagnostics and the analysis of transgenes and transgene integration sites.